EBIO Eleven biotherapeutics

[mrz687]

in after hour 200 mila pezzi scambiati e +7% a $3.8543 che ci sono news?


*

0.2443



6.77%

 

[rosalinda bs]

Buonasera . Che dite un ingresso a 0,36 ci sta?

 

[rosalinda bs]

Bene. Grazie comunque 10000 titoli li ho presi a 0,36

 

[Pablo.Escobar]

Bene. Grazie comunque 10000 titoli li ho presi a 0,36

hai dati aggiornati sulla cassa?

 

[loss&loss]

Bene. Grazie comunque 10000 titoli li ho presi a 0,36

Se hai tenuto la posizione sei a +450% nel giro di una mesata...

 

[rosalinda bs]

Se hai tenuto la posizione sei a +450% nel giro di una mesata...

Buonasera chiuse ieri a 1,67 ottimo gain, contentissima

 

[loss&loss]

Buonasera chiuse ieri a 1,67 ottimo gain, contentissima

E ci mancava anche che dopo questa performance fossi anche delusa...

Complimenti per l'acquisto ma soprattutto per aver tenuto duro nonostante guadagni importanti.

Conoscendomi, avessi comprato a 0,36 dollari, a 0,40 avrei già venduto tutto senza pensarci due volte.

 

[espa]

E ci mancava anche che dopo questa performance fossi anche delusa...

Complimenti per l'acquisto ma soprattutto per aver tenuto duro nonostante guadagni importanti.

Conoscendomi, avessi comprato a 0,36 dollari, a 0,40 avrei già venduto tutto senza pensarci due volte.

thread di 3 pagine che racchiude la vita del titolo...a volte si scrivono centinaia di pagine sul niente...non conosco questa societa' percio' non posso dire niente nel merito...mi sorprende il fatto che investitori quasi professionisti possano affermare che un titolo biotech possa stare al sicuro con 59mln di cassa 20 milioni di azioni oustanding e un trials fallito alle spalle...a me sembrano le condizioni x una lunga storia di storni...ma forse stavano ragionando esclusivamente su un trading di breve....tornando al titolo singolare come hanno risolto il problema quotazione, un rialzo galattico in poco tempo...a ripensarci in questo caso, con cosi' poche azioni un RS sarebbe stato impraticabile. ciao loss

 

[rosalinda bs]

E ci mancava anche che dopo questa performance fossi anche delusa...

Complimenti per l'acquisto ma soprattutto per aver tenuto duro nonostante guadagni importanti.

Conoscendomi, avessi comprato a 0,36 dollari, a 0,40 avrei già venduto tutto senza pensarci due volte.

certo,diciamo che la 'fortuna' é stata dalla mia parte ...avevo prefissato un prezzo di uscita tra 1$ 1,10$. per motivi di lavoro venerdi ero via e al rientro a casa lo vista su 1,70 e non ho esisitato a chiuderla, secondo me ha corso troppo e se scende ne riprendo..dispiaciuta solo di averne prese poche...ne avevo piazzate un'ulteriore lotto di 15k a 0,3 se in caso scendeva , ma va bene, una performance del genere non me l'aspettavo nel breve tempo. Saluti

 

[loss&loss]

certo,diciamo che la 'fortuna' é stata dalla mia parte ...avevo prefissato un prezzo di uscita tra 1$ 1,10$. per motivi di lavoro venerdi ero via e al rientro a casa lo vista su 1,70 e non ho esisitato a chiuderla, secondo me ha corso troppo e se scende ne riprendo..dispiaciuta solo di averne prese poche...ne avevo piazzate un'ulteriore lotto di 15k a 0,3 se in caso scendeva , ma va bene, una performance del genere non me l'aspettavo nel breve tempo. Saluti

Sei anche onesta ad aver tirato in ballo la "fortuna".
Senza voler togliere nulla alla tua favolosa operazione anche io sono convinto che la sorte abbia la sua parte, soprattutto in questo genere di operazioni.
Fortuna e sangue freddo..

Ricambio i saluti.

 

[espa]

naturalmente nel frattempo cerco di documentarmi sul titolo...credo che in questo caso, ci troviamo in presenza di una investitrice abile...il suo ingresso sul titolo e' avvenuto in coincidenza con ingressi/consolidamenti anche importanti...mi sembra dai 13/g successivamente e' stata comunicata approvazione di una linea di farmaci della societa' da parte di fda...se cosi' ottimo

praticamente il contrario di quanto avveniva fino ad agosto 2015, guando i 3 big trader suggerivano ingressi da scalper

 

[rosalinda bs]

naturalmente nel frattempo cerco di documentarmi sul titolo...credo che in questo caso, ci troviamo in presenza di una investitrice abile...il suo ingresso sul titolo e' avvenuto in coincidenza con ingressi/consolidamenti anche importanti...mi sembra dai 13/g successivamente e' stata comunicata approvazione di una linea di farmaci della societa' da parte di fda...se cosi' ottimo

praticamente il contrario di quanto avveniva fino ad agosto 2015, guando i 3 big trader suggerivano ingressi da scalper

Vi ringrazio dei complimenti...non mi ritengo una investitrice ''abile'' faccio poche operazioni mirate su stock piu blasonate(big) e difficilmente metto denaro su penny stock di basso fondo.. per mancanza di tempo e non riuscire a seguirle. su queste penny stock indovinare il timing ''giusto'' di ingresso e difficile, la ''fortuna'' ha il merito del 90% dei casi di successo. cmq Ebio la seguivo prima del fallimento del trial, poi lasciata nel dimenticatoio..ripresa in considerazioni un paio di mesi fa, ma ripeto , fa parte della sorte/destino/fortuna..come vogliamo definirla.. Saluti

 

[loss&loss]

thread di 3 pagine che racchiude la vita del titolo...a volte si scrivono centinaia di pagine sul niente...non conosco questa societa' percio' non posso dire niente nel merito...mi sorprende il fatto che investitori quasi professionisti possano affermare che un titolo biotech possa stare al sicuro con 59mln di cassa 20 milioni di azioni oustanding e un trials fallito alle spalle...a me sembrano le condizioni x una lunga storia di storni...ma forse stavano ragionando esclusivamente su un trading di breve....tornando al titolo singolare come hanno risolto il problema quotazione, un rialzo galattico in poco tempo...a ripensarci in questo caso, con cosi' poche azioni un RS sarebbe stato impraticabile. ciao loss

Ciao Espa.
Mi era sfuggito il tuo messaggio...
Cosí come un gain a tripla cifra.
Nemmeno questa volta posso cambiare nickname.

Buona serata!

 

[espa]

Ciao Espa.
Mi era sfuggito il tuo messaggio...
Cosí come un gain a tripla cifra.
Nemmeno questa volta posso cambiare nickname.

Buona serata!

se non vedevo il tuo nome non avrei conosciuto neanche il titolo...forse conoscendolo un cip insieme alla signora andava preso (rigorosamente rivenduto a 0,4)...buona serata anche a te

 

[rosalinda bs]

http://news.google.com/news/url?sa=...jFhbgI&usg=AFQjCNGFY7MtCfx5LWFNKr4Ick3GuAqrqg

Mi é parso all'occhio un pre market a -30 stamattina

cercheremo di riprenderle verso il $ ..o possibile leggermente sotto.
Saluti

 

[rosalinda bs]

Snapshot Of Analyst Recommendations: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , Tenet Healthcare Corporation (NYSE:THC)Street Updates | Street Updates

Mi é parso all'occhio un pre market a -30 stamattina

cercheremo di riprenderle verso il $ ..o possibile leggermente sotto.
Saluti

Confermato il pre market minimo 1,03 mi rimetto in acquisto 0,96 se mi riprende bene ..

 

[espa]

naturalmente nel frattempo cerco di documentarmi sul titolo...credo che in questo caso, ci troviamo in presenza di una investitrice abile...il suo ingresso sul titolo e' avvenuto in coincidenza con ingressi/consolidamenti anche importanti...mi sembra dai 13/g successivamente e' stata comunicata approvazione di una linea di farmaci della societa' da parte di fda...se cosi' ottimo

praticamente il contrario di quanto avveniva fino ad agosto 2015, guando i 3 big trader suggerivano ingressi da scalper

credo di essere un po rincodovevo stare a guardare qualche altra cosa xche non trovo + quel sec

 

[Miki & Varenne]

Eleven Biotherapeutics to Present Data at the ARVO 2016 Annual Meeting
Preclinical Data on EBI-031 in Diabetic Macular Edema and Clinical Data on Isunakinra (EBI-005) in Dry Eye Disease and Allergic Conjunctivitis to be Presented

April 29, 2016 08:32 AM Eastern Daylight Time
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that one oral presentation and three posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting taking place May 1-5, 2016, in Seattle, WA. The presentations include preclinical data for EBI-031, which is in development for diabetic macular edema and Phase 3 clinical data on isunakinra (EBI-005). Presentation abstracts can be found on the ARVO website at ARVO 216.

“We are pleased to be presenting important preclinical data on EBI-031, an IL-6 antagonist, at the ARVO Annual Meeting demonstrating characteristics that include extended therapeutic duration and rapid systemic clearance”
Tweet this
“We are pleased to be presenting important preclinical data on EBI-031, an IL-6 antagonist, at the ARVO Annual Meeting demonstrating characteristics that include extended therapeutic duration and rapid systemic clearance,” said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven Biotherapeutics. “These data support our planned submission of an investigational new drug application this quarter for the purpose of conducting clinical trials in diabetic macular edema and uveitis. In addition, we will be presenting the Phase 3 data for isunakinra in allergic conjunctivitis and dry eye disease, including post hoc evaluation of patient IL-1 genotypes and the differential clinical response to IL-1 blockade.”

Oral Presentation:

Optimized Intravitreal IL-6 Antagonist for the Treatment of Diabetic Macular Edema and Uveitis
Author: Eric Furfine, Ph.D., Eleven Biotherapeutics
Presentation #: 6017
Date/Time: Thursday, May 5, 2016 from 11:15 AM to 11:30 PM PT
Session #/Title: 525, Diabetic retinopathy
Location: Room 615/617
This presentation will discuss the findings from a non-human primate study, including half-life, immune response and potency.
Poster Presentations:

Phase 3 Multi-Center Trial Evaluating the Efficacy, Safety and Tolerability of Isunakinra in Subjects with Moderate to Severe Allergic Conjunctivitis
Author: Michael Goldstein, M.D., M.B.A., Eleven Biotherapeutics
Poster #: 2307 – C0121
Date/Time: Sunday, May 1, 2016 from 8:30 AM to 10:15 AM PT
Session #/Title: 113, Allergic conjunctivitis / Corneal Immunology and Infection
This poster describes the results of an environmental study of isunakinra compared to vehicle control given over 4 weeks in patients with moderate to severe allergic conjunctivitis.
A Multi-Center Phase 3 Safety and Tolerability Study of Isunakinra in Subjects with Moderate to Severe Dry Eye Disease
Author: Leontia Burke, Eleven Biotherapeutics
Poster #: 2872 - A0081
Date/Time: Tuesday, May 3, 2016 from 8:30 AM to 10:15 AM PT
Session #/Title: 310, Dry Eye II
This poster presents the safety profile of isunakinra given for up to 6 months in patients with moderate to severe dry eye disease.
A Phase 3 Multi-Center, Randomized Controlled Evaluation of the Efficacy, Safety and Tolerability of Isunakinra in Subjects with Moderate to Severe Dry Eye Disease
Author: Karen Tubridy, Pharm.D., Eleven Biotherapeutics
Poster #: 2874 - A0083
Date/Time: Tuesday, May 3, 2016 from 8:30 AM to 10:15 AM PT
Session #/Title: 310, Dry Eye II
The poster presentation describes the results of the efficacy trial of isunakinra compared to vehicle-control given over 12 weeks in moderate to severe dry eye disease.
About EBI-031

Eleven Biotherapeutics' most advanced preclinical product candidate is EBI-031 for treatment of diabetic macular edema, or DME, and uveitis. EBI-031 was designed and engineered for intravitreal delivery using Eleven’s AMP-Rx platform. EBI-031 is a potent blocker of both free IL-6 and IL-6 complexed to the soluble IL-6 receptor (IL-6R) and has demonstrated a longer vitreal retention time in preclinical models than antibodies and antibody like molecules approved for intravitreal injection. Eleven is undertaking the necessary manufacturing development work and nonclinical safety studies to support the submission of an investigational new drug application, or IND, to the FDA in the first half of 2016 for the purpose of conducting clinical trials of EBI-031 in DME and uveitis.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects. For more information please refer to the Company's website www.elevenbio.com.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, advancement or maturation of its product candidates and product pipeline, clinical development of the Company's product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of clinical trials and registration of product candidates, the review of its strategic alternatives and the outcome of such review, the sufficiency of its cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, the adequacy of any clinical models, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals and other factors discussed in the "Risk Factors" section of the Company's report on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission and other reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

 

[Miki & Varenne]

Eleven Biotherapeutics to Present Data at the ARVO 2016 Annual Meeting
Preclinical Data on EBI-031 in Diabetic Macular Edema and Clinical Data on Isunakinra (EBI-005) in Dry Eye Disease and Allergic Conjunctivitis to be Presented

April 29, 2016 08:32 AM Eastern Daylight Time
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that one oral presentation and three posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting taking place May 1-5, 2016, in Seattle, WA. The presentations include preclinical data for EBI-031, which is in development for diabetic macular edema and Phase 3 clinical data on isunakinra (EBI-005). Presentation abstracts can be found on the ARVO website at https://www.arvo.org/AM/Program/.

“We are pleased to be presenting important preclinical data on EBI-031, an IL-6 antagonist, at the ARVO Annual Meeting demonstrating characteristics that include extended therapeutic duration and rapid systemic clearance”
Tweet this
“We are pleased to be presenting important preclinical data on EBI-031, an IL-6 antagonist, at the ARVO Annual Meeting demonstrating characteristics that include extended therapeutic duration and rapid systemic clearance,” said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven Biotherapeutics. “These data support our planned submission of an investigational new drug application this quarter for the purpose of conducting clinical trials in diabetic macular edema and uveitis. In addition, we will be presenting the Phase 3 data for isunakinra in allergic conjunctivitis and dry eye disease, including post hoc evaluation of patient IL-1 genotypes and the differential clinical response to IL-1 blockade.”

Oral Presentation:

Optimized Intravitreal IL-6 Antagonist for the Treatment of Diabetic Macular Edema and Uveitis
Author: Eric Furfine, Ph.D., Eleven Biotherapeutics
Presentation #: 6017
Date/Time: Thursday, May 5, 2016 from 11:15 AM to 11:30 PM PT
Session #/Title: 525, Diabetic retinopathy
Location: Room 615/617
This presentation will discuss the findings from a non-human primate study, including half-life, immune response and potency.
Poster Presentations:

Phase 3 Multi-Center Trial Evaluating the Efficacy, Safety and Tolerability of Isunakinra in Subjects with Moderate to Severe Allergic Conjunctivitis
Author: Michael Goldstein, M.D., M.B.A., Eleven Biotherapeutics
Poster #: 2307 – C0121
Date/Time: Sunday, May 1, 2016 from 8:30 AM to 10:15 AM PT
Session #/Title: 113, Allergic conjunctivitis / Corneal Immunology and Infection
This poster describes the results of an environmental study of isunakinra compared to vehicle control given over 4 weeks in patients with moderate to severe allergic conjunctivitis.
A Multi-Center Phase 3 Safety and Tolerability Study of Isunakinra in Subjects with Moderate to Severe Dry Eye Disease
Author: Leontia Burke, Eleven Biotherapeutics
Poster #: 2872 - A0081
Date/Time: Tuesday, May 3, 2016 from 8:30 AM to 10:15 AM PT
Session #/Title: 310, Dry Eye II
This poster presents the safety profile of isunakinra given for up to 6 months in patients with moderate to severe dry eye disease.
A Phase 3 Multi-Center, Randomized Controlled Evaluation of the Efficacy, Safety and Tolerability of Isunakinra in Subjects with Moderate to Severe Dry Eye Disease
Author: Karen Tubridy, Pharm.D., Eleven Biotherapeutics
Poster #: 2874 - A0083
Date/Time: Tuesday, May 3, 2016 from 8:30 AM to 10:15 AM PT
Session #/Title: 310, Dry Eye II
The poster presentation describes the results of the efficacy trial of isunakinra compared to vehicle-control given over 12 weeks in moderate to severe dry eye disease.
About EBI-031

Eleven Biotherapeutics' most advanced preclinical product candidate is EBI-031 for treatment of diabetic macular edema, or DME, and uveitis. EBI-031 was designed and engineered for intravitreal delivery using Eleven’s AMP-Rx platform. EBI-031 is a potent blocker of both free IL-6 and IL-6 complexed to the soluble IL-6 receptor (IL-6R) and has demonstrated a longer vitreal retention time in preclinical models than antibodies and antibody like molecules approved for intravitreal injection. Eleven is undertaking the necessary manufacturing development work and nonclinical safety studies to support the submission of an investigational new drug application, or IND, to the FDA in the first half of 2016 for the purpose of conducting clinical trials of EBI-031 in DME and uveitis.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects. For more information please refer to the Company's website Welcome to Eleven Biotherapeutics.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, advancement or maturation of its product candidates and product pipeline, clinical development of the Company's product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of clinical trials and registration of product candidates, the review of its strategic alternatives and the outcome of such review, the sufficiency of its cash resources and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, the adequacy of any clinical models, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals and other factors discussed in the "Risk Factors" section of the Company's report on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission and other reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

 

[Miki & Varenne]

qualche millino se scende verso 0,78/80 lo rischio